JP2023022224A5 - - Google Patents

Download PDF

Info

Publication number
JP2023022224A5
JP2023022224A5 JP2022191728A JP2022191728A JP2023022224A5 JP 2023022224 A5 JP2023022224 A5 JP 2023022224A5 JP 2022191728 A JP2022191728 A JP 2022191728A JP 2022191728 A JP2022191728 A JP 2022191728A JP 2023022224 A5 JP2023022224 A5 JP 2023022224A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022191728A
Other languages
English (en)
Japanese (ja)
Other versions
JP7561814B2 (ja
JP2023022224A (ja
Filing date
Publication date
Priority claimed from US15/859,279 external-priority patent/US20180338922A1/en
Application filed filed Critical
Publication of JP2023022224A publication Critical patent/JP2023022224A/ja
Publication of JP2023022224A5 publication Critical patent/JP2023022224A5/ja
Priority to JP2024164776A priority Critical patent/JP2024178341A/ja
Application granted granted Critical
Publication of JP7561814B2 publication Critical patent/JP7561814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022191728A 2017-05-26 2022-11-30 固定用量製剤 Active JP7561814B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024164776A JP2024178341A (ja) 2017-05-26 2024-09-24 固定用量製剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762511889P 2017-05-26 2017-05-26
US62/511,889 2017-05-26
US15/859,279 US20180338922A1 (en) 2017-05-26 2017-12-29 Fixed dose formulations
US15/859,279 2017-12-29
JP2019565302A JP7187488B2 (ja) 2017-05-26 2018-05-25 固定用量製剤
PCT/US2018/034646 WO2018218147A1 (en) 2017-05-26 2018-05-25 Fixed dose formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019565302A Division JP7187488B2 (ja) 2017-05-26 2018-05-25 固定用量製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024164776A Division JP2024178341A (ja) 2017-05-26 2024-09-24 固定用量製剤

Publications (3)

Publication Number Publication Date
JP2023022224A JP2023022224A (ja) 2023-02-14
JP2023022224A5 true JP2023022224A5 (https=) 2023-04-10
JP7561814B2 JP7561814B2 (ja) 2024-10-04

Family

ID=62621055

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019565302A Active JP7187488B2 (ja) 2017-05-26 2018-05-25 固定用量製剤
JP2022191728A Active JP7561814B2 (ja) 2017-05-26 2022-11-30 固定用量製剤
JP2024164776A Pending JP2024178341A (ja) 2017-05-26 2024-09-24 固定用量製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019565302A Active JP7187488B2 (ja) 2017-05-26 2018-05-25 固定用量製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024164776A Pending JP2024178341A (ja) 2017-05-26 2024-09-24 固定用量製剤

Country Status (15)

Country Link
US (2) US20180338922A1 (https=)
EP (1) EP3630070A1 (https=)
JP (3) JP7187488B2 (https=)
KR (3) KR20250109242A (https=)
CN (1) CN110996914A (https=)
AU (2) AU2018272040A1 (https=)
BR (1) BR112019024747A2 (https=)
CA (1) CA3064895A1 (https=)
CL (1) CL2019003437A1 (https=)
IL (2) IL270866B2 (https=)
MX (2) MX2019014122A (https=)
PH (1) PH12019502782A1 (https=)
TW (1) TWI798228B (https=)
UA (1) UA126451C2 (https=)
WO (1) WO2018218147A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
AU2019221765A1 (en) * 2018-02-16 2020-09-10 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
US20210322375A1 (en) * 2018-08-27 2021-10-21 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions
EP3666750A1 (en) * 2018-12-10 2020-06-17 Sandoz AG Crystalline form of bempedoic acid
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
MX2021015936A (es) 2019-06-21 2022-04-26 Esperion Therapeutics Inc Metodos para preparar acido bempedoico y composiciones del mismo.
US12528759B2 (en) 2019-10-03 2026-01-20 Synthon B.V. Crystalline forms of bempedoic acid
US12516013B2 (en) 2019-12-06 2026-01-06 Synthon B.V. Crystalline forms of sodium salt of Bempedoic acid
CN115379861A (zh) * 2020-04-10 2022-11-22 日本瓦姆&珀巴尔株式会社 缓释性主剂
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法
WO2021255180A1 (en) 2020-06-19 2021-12-23 Synthon B.V. Salts of bempedoic acid
US20250134841A1 (en) 2021-09-13 2025-05-01 Synthon B.V. Pharmaceutical composition of bempedoic acid
CA3256768A1 (en) 2022-05-09 2023-11-16 Renata Pharmaceutical (Ireland) Ltd PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID
JP2024116544A (ja) * 2023-02-16 2024-08-28 株式会社三共 遊技機
JP2024116545A (ja) * 2023-02-16 2024-08-28 株式会社三共 遊技機

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
JP4438268B2 (ja) 2001-03-07 2010-03-24 大日本住友製薬株式会社 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2625429T3 (es) 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
ES2382773T3 (es) * 2009-03-13 2012-06-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Composiciones de ezetimiba
CA2755274C (en) * 2009-03-13 2017-02-28 Sahoe Kakuda Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
PT2459175T (pt) * 2009-07-28 2018-02-07 Egyt Gyogyszervegyeszeti Gyar Novo processo de granulação e o granulado assim preparado
CN101926756B (zh) * 2010-08-12 2012-01-18 北京赛科药业有限责任公司 一种氯吡格雷或其药学上可接受盐的固体制剂
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
CA2845228C (en) * 2011-08-16 2021-08-10 Baker Idi Heart & Diabetes Institute Holdings Limited Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds
MX378845B (es) * 2014-01-21 2025-03-10 Bpsi Holdings Llc Revestimientos de pelicula de liberacion inmediata que contienen gliceridos de cadena media y sustratos revestidos con los mismos.
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
HK1257929A1 (zh) * 2015-11-06 2019-11-01 Gemphire Therapeutics Inc. 治疗混合性血脂异常

Similar Documents

Publication Publication Date Title
JP2022068302A5 (https=)
JP2022028828A5 (https=)
JP2022025124A5 (https=)
JP2021185136A5 (https=)
JP2023116721A5 (https=)
JP2021169491A5 (https=)
JP2024059739A5 (https=)
JP2024023385A5 (https=)
JP2023022224A5 (https=)
JP2021038271A5 (https=)
JP2024016014A5 (https=)
JP2023100643A5 (https=)
JP2022060295A5 (https=)
JP2025506484A5 (https=)
JP2022537813A5 (https=)
JP2020171301A5 (https=)
JP2020120660A5 (https=)
JP2024112817A5 (https=)
JP2023085551A5 (https=)
JP2024534771A5 (https=)
JP2025084837A5 (https=)
JP2023011759A5 (https=)
JP2022022379A5 (https=)
JP2022172276A5 (https=)
JP2020141705A5 (https=)